Viatris’ Once-Monthly Copaxone Filing Imminent, Botox ‘On Track’
Recent Approval For Revance Brand Encourages Viatris On Botox
Fresh from offloading almost all its interests in biosimilars to Biocon, Viatris continues to develop several follow-on products, which it hopes will add $1bn to the company’s top line by the end of the decade.
You may also be interested in...
Viatris and Mapi have moved a step closer to realizing the US launch of their 505(b)(2) once-
After reporting sliding sales for both generics and complex generics in Q1, Viatris has nevertheless reaffirmed its commitment to the off-patent sector, highlighting in particular a planned launch this year of its Breyna rival to Symbicort.
One Copaxone (glatiramer acetate) ANDA sponsor is suing another for alleged patent infringement, with Momenta filing a lawsuit against Viatris and its partners in a US district court.